Arcturus Therapeutics Holdings Inc. reported $29M of revenue over the trailing twelve months, −76% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $29M (to Q2 2026). Net income: −$93M, trailing twelve months to Q2 2026. Free cash flow: −$73M, trailing twelve months to Q2 2026. Operating margin: −700%, trailing twelve months to Q2 2026.

ARCTArcturus Therapeutics Holdings Inc.

Healthcare

$6.82-49% 1Y

$6.82

$5.5252 weeks$23.16

ARCT as reported

Arcturus Therapeutics Holdings Inc. reported $29M of revenue over the trailing twelve months, −76% on the year before. 10 reported series are charted on this page, each one as filed.

$29M

Revenue, trailing twelve months · to Q2 2026 · −76% against the twelve months before

Net income: −$93M
Net income · +55% year on year · trailing twelve months to Q2 2026
Free cash flow: −$73M
Free cash flow · +12% year on year · trailing twelve months to Q2 2026
Operating margin: −700%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ARCT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$29M	−76%	Q2 2026
Net income	−$93M	+55%	Q2 2026
EPS	−$3.33	+49%	Q2 2026
Operating margin	−700%	n/a	Q2 2026
Net margin	−649%	n/a	Q2 2026
ROE	−39%	n/a	Q2 2026
ROA	−30%	n/a	Q2 2026
ROIC	205%	n/a	Q4 2022 · 14 quarters behind
Free cash flow	−$73M	+12%	Q2 2026
P/E	17.7	n/a	Q3 2023 · 11 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.